Merck, Modifi

Merck buys cancer therapy developer Modifi Biosciences for up to $1.3 bln
Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm said on Wednesday.
Merck buys Modifi for $30M plus up to $1.3B in potential payments
Merck (NYSE:MRK) has acquired Modifi Biosciences, a developer of DNA modification-enabled cancer drugs, for $30M upfront and up to $1.3B in potential milestone payments. Modifi, a spinout of Yale University,
Merck sets sights on brain cancer with $30M Modifi acquisition
Merck & Co. is putting down $30 million cash to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset designed to take on the tough-to-treat brain cancer glioblastoma.
Merck acquires Yale-spinout Modifi Bio in $1.3B deal
Modifi Biosciences, a New Haven startup biotech that focuses on developing cancer therapies, has been acquired by biopharmaceutical giant Merck & Co. Inc. in a $1.3 billion deal, the companies announced Wednesday.
Merck acquires Modifi Biosciences for $30M upfront
Modifi Biosciences announced that the company has been acquired by Merck (MRK). Under the terms of the agreement Merck, through a subsidiary,
Merck & Co buys Modifi Biosciences
Connecticut, USA-based Modifi Biosciences today announced that the company has been acquired by pharma giant Merck & Co (NYSE: MRK). Modifi Biosciences was formed in 2021 based on technology spun out of Yale University.
Merck Buys Yale Cancer-Therapy Spinout Modifi Biosciences
Merck & Co. has acquired Modifi Biosciences, a developer of cancer therapies that was spun out of Yale University, in a deal potentially worth more than $1 billion.
Merck buys cancer therapy developer Modifi Biosciences for up to $1.3 billion
Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm said on Wednesday. As part of the deal, the U.S.
Modifi Biosciences Acquired by Merck
In founding Modifi Biosciences, we sought to radically change the oncology treatment paradigm for cancer patients with glioblastoma and other tumors,” said Ranjit S. Bindra, MD, PhD, Modifi Biosciences Co-founder,
BioWorld23h
Modifi acquired by Merck in $1.3B deal
Modifi Biosciences Inc. has come a long way very quickly. Spun out of Yale University in 2021, it published data on DNA ...
Benzinga.com5d
What's Going On With Bright Minds Biosciences Stock Friday?
Bright Minds Biosciences announced a non-brokered private placement with expected gross proceeds of $35 million. The company's stock is currently trading with a session volume of about 10.6 million.
Seeking Alpha5d
EVFM Evofem Biosciences, Inc.
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women’s sexual and reproductive health. Its commercial product is ...
Investing1d
Caribou Biosciences Inc (CRBU)
BERKELEY, CA - Caribou Biosciences, Inc., a company specializing in biological products, announced the upcoming resignation of its Chief Financial Officer (CFO ...